Medical Condition: Asthma
Purpose of Study: To evaluate the safety and effectiveness of dupilumab in patients with persistent asthma
- 12 years of age and older
- Diagnosed with asthma for at least 12 months
Treatment with an inhaled corticosteroid and a second controller medication for at least 3 months. Examples of inhaled corticosteroids include, but are not limited to Advair Diskus® or Advair HFA®, Symbicort®, Dulera®, Flovent Diskus® or Flovent HFA®, and Pulmicort®. Examples of secondary controller medication includes, but are not limited to Serevent Diskus®, Foradil®, Singulair®, Accolate®, and Theophylline.
At least 1 asthma flare-up in the past 12 months requiring either treatment with a systemic corticosteroid OR emergency medical care or hospitalization. Examples of systemic corticosteroids include, but are not limited to prednisone, prednisolone, methylprednisolone, and dexamethasone.
Compensation: There is no cost to you to take part in this study. Qualified participants may receive all study related care and study medication at no cost. YOU WILL BE COMPENSATED FOR YOUR TIME AND TRAVEL.
Please contact Heather at 971-220-2208, extension 2, for additional information about the study.